• Cardiac Imaging in the VALOR-HCM Trial

  • Nov 21 2024
  • Length: 31 mins
  • Podcast

Cardiac Imaging in the VALOR-HCM Trial

Listen for free

View show details

  • Summary

  • Mavacamten is the first and only FDA-approved cardiac myosin inhibitor to treat obstructive hypertrophic cardiomyopathy (HCM). An important factor to the success of the VALOR HCM trial was the participation of specialized cardiac sonographers and imagers.
    Milind Desai, MD, MBA speaks with Jeanne Drinko, Amy Kanta and Anne Campbell about the importance of cardiac imaging.


    Learn more about C5 Research at Cleveland Clinic.
    https://my.clevelandclinic.org/research/c5research

    Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET), toll-free 800.223.2273, ext. 49162
    Show More Show Less
Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Cardiac Imaging in the VALOR-HCM Trial

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews
No Reviews are Available